 Homology Medicines NASDAQ:FIXX was upgraded by Zacks Investment Research from a sell rating to a hold rating in a note issued to investors on Monday, Zacks.com reports. According to Zacks, Homology Medicines Inc. is a genetic medicines company. Its platform offers human hematopoietic stem cell derived adeno-associated virus vectors to treat disease-causing mutations through gene ... 